Stockscreener 앱 받기
3.61
2.96%
-0.11
전일 마감가:
$3.72
열려 있는:
$3.74
하루 거래량:
414.23K
Relative Volume:
0.43
시가총액:
$300.34M
수익:
$14.20M
순이익/손실:
$-49.59M
주가수익비율:
-4.2854
EPS:
-0.8424
순현금흐름:
$-35.25M
1주 성능:
-1.37%
1개월 성능:
+1.40%
6개월 성능:
-0.82%
1년 성능:
+205.93%
1일 변동 폭
$3.56
$3.75
1주일 범위
$3.56
$3.99
52주 변동 폭
$1.10
$5.81
Opus Genetics Inc Stock (IRD) Company Profile
명칭
Opus Genetics Inc
전화
248-681-9815
주소
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
3.61 | 312.82M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-16 | 개시 | Oppenheimer | Outperform |
| 2026-01-20 | 개시 | BTIG Research | Buy |
| 2025-12-10 | 개시 | B. Riley Securities | Buy |
| 2025-11-25 | 개시 | Piper Sandler | Overweight |
| 2025-10-29 | 개시 | Wedbush | Outperform |
| 2025-10-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-11 | 개시 | Craig Hallum | Buy |
| 2024-11-13 | 재개 | H.C. Wainwright | Buy |
모두보기
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics (NASDAQ:IRD) Rating Increased to Hold at Zacks Research - MarketBeat
Opus Genetics Q3 EPS Lifted by Brookline Capital Markets - MarketBeat
Brokers Set Expectations for Opus Genetics FY2030 Earnings - MarketBeat
Opus Genetics FY2026 EPS Estimate Boosted by HC Wainwright - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development Strategy - Clinical Leader
Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy - glance.eyesoneyecare.com
Opus Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Opus Genetics Inc (IRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Opus Genetics (IRD) Gets a Buy from RBC Capital - The Globe and Mail
Piper Sandler Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Is Opus Genetics Inc (IRD) Significantly Overvalued After Q2 Ear - GuruFocus
OPUS GENETICSMAY OFFER AND SELL UP TO $300 MLN OF SECURITIESSEC FILING - Moomoo
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
IRD Maintained by RBC Capital -- Price Target Lowered to $9.00 - GuruFocus
A. G. P. Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $9 to $10 - Moomoo
Opus GeneticsMay Offer And Sell Up To $300 Million Of SecuritiesSEC Filing - TradingView
RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating - marketscreener.com
Opus Genetics (NASDAQ: IRD) sets $300M shelf and $125M ATM stock plan - Stock Titan
Opus Genetics earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Opus Genetics (NASDAQ:IRD) Releases Earnings Results - MarketBeat
Opus Genetics, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.14) — 10-Q Summary - TradingView
Opus Genetics (Nasdaq: IRD) hit by $73.6M loss, rising warrant costs - Stock Titan
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Opus Genetics Q2 revenue falls and misses estimates - TradingView
IRD: Gene therapy pipeline advances with strong cash position and key clinical milestones ahead - TradingView
Opus Genetics Reports Q2 2026 Results and Advances Multiple IRD Gene Therapy Programs with OPGx-BEST1 Data Expected in September - quiverquant.com
Opus Genetics reports Q2 2026 results: $0.8M revenue, $8.1M net loss, $88.8M cash - TradingView
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update - GlobeNewswire
Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Opus Genetics Completes Phase 3 Enrollment for AAV Gene Therapy OPGx-LCA5 - BioPharm International
Opus Genetics (IRD) to Release Quarterly Earnings on Wednesday - MarketBeat
BTIG Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Opus Genetics completes enrollment in LCA5 gene therapy trial - Investing.com
Opus Genetics completes enrollment in LCA5 gene therapy trial By Investing.com - Investing.com South Africa
Opus Genetics Completes Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 For LCA5-Associated Inherited Retinal Disease - marketscreener.com
Opus Genetics completes patient enrollment in P... - Pluang
Opus Genetics, Inc. $IRD Shares Sold by Perceptive Advisors LLC - MarketBeat
Opus Genetics, Inc. Revenue Breakdown – NASDAQ:IRD - TradingView
Opus Genetics Inc (IRD) Institutional Confidence - tradingkey.com
TD Cowen Initiates Opus Genetics at Buy - marketscreener.com
Opus Genetics, Inc. Revenue Breakdown – FWB:R3X1 - TradingView
Opus Genetics Inc (IRD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Opus Genetics CFO Robert Gagnon sells $22,941 in company stock - Investing.com
Form 4 Opus Genetics Inc For: 27 July By Investing.com - Investing.com India
Opus Genetics COO Joseph Schachle sells $13,653 in common stock By Investing.com - Investing.com Canada
Opus Genetics CEO George Magrath sells $27,925 in common stock By Investing.com - Investing.com Canada
Opus Genetics COO Joseph Schachle sells $13,653 in common stock - Investing.com
Opus Genetics CEO George Magrath sells $27,925 in common stock - Investing.com
Opus Genetics President Benjamin Yerxa Executes Automatic Sale of 7,429 Shares to Cover RSU Tax Withholding - Kalkine Media
Opus Genetics Inc (IRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):